Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218034 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT02218034 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 78 participants.
The verdict
NCT02218034, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
Interventions
- DRUG AGN-190168 Formulation 1
- DRUG AGN-190168 Formulation 2
- DRUG tazarotene gel 0.1%
- DRUG tazarotene cream 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02218034
The ClinicalTrials.gov registry entry for NCT02218034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AGN-190168 Formulation 1 is the first listed.
NCT02218034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02218034 about?
NCT02218034 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris". This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
What is the current status of trial NCT02218034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2014-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02218034?
The interventions under investigation include: AGN-190168 Formulation 1 (DRUG), AGN-190168 Formulation 2 (DRUG), tazarotene gel 0.1% (DRUG), tazarotene cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT02218034?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.